Introduction This study investigated the characteristics and trends of therapeutic medication errors reported to United States (US) poison centers that occurred in a non-healthcare facility setting and were associated with hospital admission. Methods Using a retrospective cohort design, National Poison Data System data from 2000 to 2024 were analyzed. US Census Bureau data were used to calculate population-based rates. Results...

Introduction As glucagon-like peptide-1 receptor agonist (GLP-1) use has increased among children, a better understanding of the related adverse effects in this population is needed. Methods National Poison Data System data from 2017 to 2024 were analyzed to compare characteristics and trends of exposures involving GLP-1s reported to United States (US) poison centers (PCs) among children 6–17 years old with those of adults. Re...

Introduction This study investigated the characteristics and trends of pediatric exposures to caffeine energy products reported to US poison centers Methods National Poison Data System data for caffeine energy product single-substance exposures during 2011–2023 among individuals < 20 years old were analyzed. Results There were 32,482 caffeine energy product exposures reported to US poison centers with a 17.3% exposure rate inc...

Introduction Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications for management of diabetes and obesity. The objective of this study is to characterize the epidemiology of GLP-1RA cases reported to US poison centers. Methods We analyzed cases involving a GLP-1RA reported to the National Poison Data System during 2017–2022. Results There were 5,713 single-substance exposure cases reported to US poiso...